Nypozi (filgrastim-txid) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME	:	MEMBER'S FIRST NAME:			
	view (e.g., chart notes o	or lab data, to support th	r. Attach any additional documenta e authorization request). Informati		
			☐ URG	ENT	
MEMBER INFORMATIO	N				
LAST NAME:	T NAME: FIR:		FIRST NAME:		
PHONE NUMBER:		DATE OF BIRTH:			
STREET ADDRESS:		·			
CITY:		STATE:	ZIP CODE:		
PATIENT INSURANCE	D NUMBER:				
☐ MALE ☐ FEMALE	HEIGHT (IN/CM):	WEIGHT (LB/KG):	ALLERGIES:		
PATIENT'S AUTHORIZE AUTHORIZED REPRESE	<u>IETHERAPEUTICS.CC</u> D REPRESENTATIVE (<u>OM/NOPP</u> (IF APPLICABLE):	I CAN BE FOUND AT THE		
PRESCRIBER INFORM	ATION				
LAST NAME:		FIRST NAME:	FIRST NAME:		
PRESCRIBER SPECIALTY:		EMAIL ADDRES	EMAIL ADDRESS:		
NPI NUMBER:		DEA NUMBER:	DEA NUMBER:		
PHONE NUMBER:		FAX NUMBER:	FAX NUMBER:		
STREET ADDRESS:					
CITY:		STATE:	STATE: ZIP CODE:		
REQUESTER (if different than prescriber):		OFFICE CONTA	OFFICE CONTACT PERSON:		
		-			
MEDICATION OR MEDI	CAL DISPENSING INF	ORMATION			
MEDICATION NAME:					
DOSE/STRENGTH:	FREQUENCY:	LENGTH OF THERAPY/REF	QUANTITY:		
☐ NEW THERAPY	RENEWAL	F RENEWAL: DATE T			
DURATION OF THERAF	Y (SPECIFIC DATES):				
Continued on next page					

©2017-2024 Prime Therapeutics Management LLC, a Prime Therapeutics company Prime Therapeutics Management – Commercial Clients. Revision Date: 11.1.25 CAT009



Nypozi (filgrastim-txid) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:	MEMBER'S FIRST N	IAME:				
1. HAS THE PATIENT TRIED ANY OTHER MEDICATIONS FOR THIS CONDITION? YES (if yes, complete below) NO						
MEDICATION/THERAPY (SPECIFY DRUG NAME AND DOSAGE):	DURATION OF THERAPY (SPECIFY DATES):	RESPONSE/REASON FOR FAILURE/ALLERGY:				
2. LIST DIAGNOSES:		ICD-10:				
Other diagnosis:	ICD-10 Code(s):					
3. REQUIRED CLINICAL INFORMATO SUPPORT A PRIOR AUTHORI	ATION: PLEASE PROVIDE ALL REL ZATION.	EVANT CLINICAL INFORMATION				
Is patient going to be using drug	in combination with a clinical trial	? ☐ Yes ☐ No				
Has patient used the preferred product Nivestym (filgrastim-aafi)? Yes No						
Does patient have an absolue contraindication to Nivestym(filgrastim-aafi)? Yes No						
Is the prescribed medication being used to prevent febrile neutropenia in a previously untreated adult or pediatric patient? □ Yes □ No						
Does the patient have a diagnosis of a non-myeloid malignancy and is the patient receiving chemotherapy and/or radiotherapy with an expected incidence of febrile neutrophenia of 20% or greater? No						
Is the patient at an increased risk for developing chemotherapy-induced infections due to any of the following reasons?						
amounts of bone	or 1,000/mm° or less) emotherapy ○Previous exposure o	f pelvis or other areas of large				
marrow to radiation □ History of recurrent febrile neutropenia from chemotherapy □ Patient is 65 years of age or older						
□ Patient has a condition that can potentially increase the risk of serious infection (i.e., HIV/AIDS) *Please submit documentation						
	IT or myelodysplasia-related neutr	ropenia				
 □ ANC of 500/mm³ or less with HIV/AIDS □ ANC of 1,5000/mm³ or less with severe chronic neutropenia of congenital, cyclic or idiopathic origin or for use 						
with peripheral blood progenitors						
□ WBC count less than 3.0 K/μL (3,000 cells/mm²) and is post-transplantation of the liver or kidney						

©2017-2024 Prime Therapeutics Management LLC, a Prime Therapeutics company Prime Therapeutics Management – Commercial Clients. Revision Date: 11.1.25 CAT009



Nypozi (filgrastim-txid) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:	MEMBER'S F	FIRST NAME:			
*Please submit documentation.					
Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?					
Please note: Not all drugs/diagnosis are required information is received.	covered on all plans. Th	nis request may be denied unless all			
ATTESTATION: I attest the information understand that the Health Plan, insurer, request the medical information necessar	, Medical Group or its des	signees may perform a routine audit and			
Prescriber Signature or Electronic I.D	. Verification:	Date:			
confidentiality notice: The docu information that is legally privileged. If you disclosure, copying, distribution, or action prohibited. If you have received this information FAX) and arrange for the return or destruction.	ou are not the intended re n taken in reliance on the rmation in error, please n	e contents of these documents is strictly otify the sender immediately (via return			

FAX THIS FORM TO: 800-424-7640

MAIL REQUESTS TO: Prime Therapeutics Management Prior Authorization Program
Attn: CP-4201

P.O. Box 64811 St. Paul, MN 55164-0811 **Phone**: 877-228-7909

